AU2015269667B2 - Methods of increasing tonic inhibition and treating secondary insomnia - Google Patents

Methods of increasing tonic inhibition and treating secondary insomnia Download PDF

Info

Publication number
AU2015269667B2
AU2015269667B2 AU2015269667A AU2015269667A AU2015269667B2 AU 2015269667 B2 AU2015269667 B2 AU 2015269667B2 AU 2015269667 A AU2015269667 A AU 2015269667A AU 2015269667 A AU2015269667 A AU 2015269667A AU 2015269667 B2 AU2015269667 B2 AU 2015269667B2
Authority
AU
Australia
Prior art keywords
thip
pharmaceutically acceptable
acceptable salt
sleep
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015269667A
Other languages
English (en)
Other versions
AU2015269667A1 (en
Inventor
Matthew During
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of AU2015269667A1 publication Critical patent/AU2015269667A1/en
Application granted granted Critical
Publication of AU2015269667B2 publication Critical patent/AU2015269667B2/en
Priority to AU2020217342A priority Critical patent/AU2020217342B2/en
Priority to AU2022200085A priority patent/AU2022200085A1/en
Priority to AU2024202604A priority patent/AU2024202604A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AU2015269667A 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia Active AU2015269667B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2020217342A AU2020217342B2 (en) 2014-06-06 2020-08-11 Methods of increasing tonic inhibition and treating secondary insomnia
AU2022200085A AU2022200085A1 (en) 2014-06-06 2022-01-07 Methods of increasing tonic inhibition and treating secondary insomnia
AU2024202604A AU2024202604A1 (en) 2014-06-06 2024-04-22 Methods of increasing tonic inhibition and treating secondary insomnia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06
US62/008,939 2014-06-06
PCT/US2015/034018 WO2015187851A1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020217342A Division AU2020217342B2 (en) 2014-06-06 2020-08-11 Methods of increasing tonic inhibition and treating secondary insomnia

Publications (2)

Publication Number Publication Date
AU2015269667A1 AU2015269667A1 (en) 2016-12-22
AU2015269667B2 true AU2015269667B2 (en) 2020-07-30

Family

ID=54767324

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2015269667A Active AU2015269667B2 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia
AU2020217342A Active AU2020217342B2 (en) 2014-06-06 2020-08-11 Methods of increasing tonic inhibition and treating secondary insomnia
AU2022200085A Abandoned AU2022200085A1 (en) 2014-06-06 2022-01-07 Methods of increasing tonic inhibition and treating secondary insomnia
AU2024202604A Pending AU2024202604A1 (en) 2014-06-06 2024-04-22 Methods of increasing tonic inhibition and treating secondary insomnia

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2020217342A Active AU2020217342B2 (en) 2014-06-06 2020-08-11 Methods of increasing tonic inhibition and treating secondary insomnia
AU2022200085A Abandoned AU2022200085A1 (en) 2014-06-06 2022-01-07 Methods of increasing tonic inhibition and treating secondary insomnia
AU2024202604A Pending AU2024202604A1 (en) 2014-06-06 2024-04-22 Methods of increasing tonic inhibition and treating secondary insomnia

Country Status (20)

Country Link
US (11) US20150352085A1 (enExample)
EP (3) EP3795156A1 (enExample)
JP (4) JP2017516868A (enExample)
AR (1) AR100772A1 (enExample)
AU (4) AU2015269667B2 (enExample)
CA (1) CA2950845C (enExample)
CY (2) CY1124366T1 (enExample)
DK (2) DK3151832T3 (enExample)
ES (2) ES2875742T3 (enExample)
HR (2) HRP20210901T1 (enExample)
HU (2) HUE055400T2 (enExample)
IL (2) IL249287B (enExample)
LT (2) LT3151832T (enExample)
MX (2) MX391502B (enExample)
PL (2) PL3151832T3 (enExample)
PT (2) PT3151832T (enExample)
RS (2) RS62007B1 (enExample)
SI (2) SI3151832T1 (enExample)
SM (2) SMT202100343T1 (enExample)
WO (1) WO2015187851A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3065782B8 (en) 2013-11-05 2021-05-26 Elena Molokanova Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels
EP3795156A1 (en) 2014-06-06 2021-03-24 Ovid Therapeutics, Inc. Pharmaceutical composition for treating angelman syndrome
US10080898B2 (en) 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
EP3528807A4 (en) * 2016-11-22 2020-06-17 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
EP3833351A4 (en) * 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
KR20210110585A (ko) * 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
JP2022524927A (ja) 2019-02-02 2022-05-11 ステモニックス インコーポレイティド 創薬のためのヒトスフェロイドの使用方法
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
EP3982937A4 (en) * 2019-07-15 2022-08-10 Ovid Therapeutics Inc. PHARMACEUTICAL FORMULATIONS WITH GABOXADOL FOR THERAPEUTIC TREATMENT
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
JP7600661B2 (ja) * 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤
AU2024220869A1 (en) 2023-02-17 2025-09-04 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929065A (en) * 1995-07-13 1999-07-27 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Method for treating sleep disorders
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
JP5909750B2 (ja) 2007-11-13 2016-04-27 マリンクロット アイピー 低用量静脈内アセトアミノフェン
CN102137667A (zh) * 2008-09-01 2011-07-27 H.隆德贝克有限公司 包含加波沙朵和patl或oat抑制剂的药物组合物
EP3795156A1 (en) * 2014-06-06 2021-03-24 Ovid Therapeutics, Inc. Pharmaceutical composition for treating angelman syndrome
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929065A (en) * 1995-07-13 1999-07-27 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Method for treating sleep disorders
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EGAWA, K et al., "Decreased Tonic Inhibition in Cerebellar Granule Cells Causes Motor Dysfunction in a Mouse Model of Angelman Syndrome", Sci Transl Med, vol. 4, no. 163, (2012-01-10) *
JOSE LUIS OLMOS-SERRANO ET AL, "The GABAsubA/sub Receptor Agonist THIP Ameliorates Specific Behavioral Deficits in the Mouse Model of Fragile X Syndrome", DEVELOPMENTAL NEUROSCIENCE., (2011-01-01), vol. 33, no. 5,pages 395 - 403 *
WALSH ET AL, "The Selective Extrasynaptic GABAA Agonist, Gaboxadol, Improves Traditional Hypnotic Efficacy Measures and Enhances Slow Wave Activity in a Model of Transient Insomnia", SLEEP, (2007-01-01), vol. 30, no. 5, pages 593 - 602 *

Also Published As

Publication number Publication date
US20160038469A1 (en) 2016-02-11
JP2021178836A (ja) 2021-11-18
EP3151832A1 (en) 2017-04-12
IL249287B (en) 2021-03-25
MX2020012404A (es) 2022-04-11
US20170071917A1 (en) 2017-03-16
LT3372229T (lt) 2021-07-12
AR100772A1 (es) 2016-11-02
JP2020063264A (ja) 2020-04-23
CY1124366T1 (el) 2022-07-22
PT3372229T (pt) 2021-06-17
US20180015076A1 (en) 2018-01-18
DK3372229T3 (da) 2021-06-14
US20250025448A1 (en) 2025-01-23
SI3151832T1 (sl) 2021-08-31
MX380868B (es) 2025-03-12
AU2020217342B2 (en) 2021-10-07
IL268960B (en) 2021-05-31
US11278529B2 (en) 2022-03-22
US9339495B2 (en) 2016-05-17
IL249287A0 (en) 2017-02-28
IL268960A (en) 2019-10-31
HRP20210901T1 (hr) 2021-09-17
CY1124368T1 (el) 2022-07-22
WO2015187851A1 (en) 2015-12-10
US9744159B2 (en) 2017-08-29
SMT202100343T1 (it) 2021-07-12
EP3372229B1 (en) 2021-03-24
US20170087133A1 (en) 2017-03-30
HRP20210902T1 (hr) 2021-09-17
ES2875742T3 (es) 2021-11-11
US20230051859A1 (en) 2023-02-16
AU2020217342A1 (en) 2020-08-27
CA2950845C (en) 2023-04-25
PT3151832T (pt) 2021-06-15
CA2950845A1 (en) 2015-12-10
LT3151832T (lt) 2021-07-12
MX2016016136A (es) 2017-07-05
ES2876350T3 (es) 2021-11-12
AU2015269667A1 (en) 2016-12-22
AU2024202604A1 (en) 2024-05-09
HUE055155T2 (hu) 2021-11-29
US20220016091A1 (en) 2022-01-20
EP3151832B1 (en) 2021-03-24
US9801864B2 (en) 2017-10-31
US20180303805A1 (en) 2018-10-25
JP2023123442A (ja) 2023-09-05
RS62007B1 (sr) 2021-07-30
PL3372229T3 (pl) 2021-10-04
SMT202100340T1 (it) 2021-07-12
JP2017516868A (ja) 2017-06-22
SI3372229T1 (sl) 2021-09-30
US20160228418A1 (en) 2016-08-11
RS62006B1 (sr) 2021-07-30
PL3151832T3 (pl) 2021-10-25
EP3795156A1 (en) 2021-03-24
HUE055400T2 (hu) 2021-11-29
AU2022200085A1 (en) 2022-02-03
DK3151832T3 (da) 2021-06-14
US9446028B2 (en) 2016-09-20
US20170273956A1 (en) 2017-09-28
MX391502B (es) 2025-03-21
EP3151832A4 (en) 2018-01-17
US20150352085A1 (en) 2015-12-10
EP3372229A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
AU2020217342B2 (en) Methods of increasing tonic inhibition and treating secondary insomnia
WO2015171547A1 (en) Methods of treating cognitive impairment associated with neurodegenerative disorders
CN119095595A (zh) 用于治疗睡眠紊乱的5-meo-dmt
AU2006256851A1 (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
EP4427738A2 (en) Dosing protocols and regimens for aminosterol treatment
AU2023336222A1 (en) Use of mdma for treatment of stress-related disorders
WO2015153971A1 (en) Methods of treating sleep disorders associated with neurodegenerative diseases
CN118973571A (zh) 认知功能障碍的治疗
HK1260775B (en) Methods of increasing tonic inhibition and treating angelman syndrome
HK1260775A1 (en) Methods of increasing tonic inhibition and treating angelman syndrome
HK40107764A (en) Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof
KR20160146872A (ko) 이명 환자의 치료용 약제

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)